SEC Form 4 · accession 0000943819-26-000038
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael J. Farrell
Officer — Chairman and CEO · Director
Period of report
Jul 7, 2026
Accepted (ET)
Jul 9, 2026 · 7:40 am EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Jul 7, 2026 | M | 4,991 | $146.34 | A | 471,214 | D | |
| ResMed Common StockF2 | Jul 7, 2026 | S | 4,991 | $218.5475 | D | 466,223 | D | |
| ResMed Common Stock | holding | — | — | — | 2,090 | I | Lisette and Michael Farrell Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock OptionsF3 | $146.34 | Jul 7, 2026 | M | 4,991 | D | Nov 11, 2020 | Nov 21, 2026 | ResMed Common Stock | 4,991 | 19,966 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
- F2This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price.
- F3Represents date options first become exercisable. Options vest 1/3 per year.